Blog

Aakash Desai: LUPER – Lurbinectedin plus pembrolizumab in SCLC

Aakash Desai/LinkedIn

Feb 12, 2025, 08:59

Aakash Desai: LUPER – Lurbinectedin plus pembrolizumab in SCLC

Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, shared an article Antonio Calles and colleagues authored post on X:

“In JTO online, LUPER: lurbinectedin + pembrolizumab in SCLC

• RR: 46.4% (3 CR)
• DOR: 7.8m | PFS: 4.6m | OS: 10.5m

My Takeaway? Limited impact—IO is standard in 1L, and emerging 2L options post-IO show strong efficacy as well.”

Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer (SCLC): the phase I/II LUPER study

Authors: Antonio Calles et al.

Aakash Desai: LUPER - Lurbinectedin plus pembrolizumab in SCLC

Aakash Desai Alejandro Navarro Antonio Calles Bernard Gaston Doger Speville Uribe cancer Daniel Alcalá-López Elena Corral de la Fuente Emiliano Calvo Enric Álvarez Colomé Enriqueta Felip Ernest Nadal Jorge Ramon-Patino Jose Rodríguez-Morató Maria de Miguel Maria Jove Marta Arregui Melissa Fernández-Pinto Olga Boix OncoDaily Oncology Pedro Rocha Ramón Palmero Rosa Álvarez Victor Moreno

New Paper Alert: Management of Immune Checkpoint Inhibitor-Associated Toxicities in Older Adults with Cancer

Kimryn Rathmell was Awarded 2025 ACS Medal of Honor

VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer

New Paper Alert: HARMONi-2 study of Ivonescimab vs pembrolizumab for PD-L1-positive non-small cell lung cancer

We are thrilled to welcome Dr. Jasmine Kamboj to the OncoDaily Editorial Board!